Interviews

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

Arnab Basu, MD, MPH, FACP, discussed his research on high-sensitivity circulating tumor DNA assays in genitourinary malignancies.

Christos Vaklavas, MD, discusses the results of the TROPION-Breast01 trial of datopotamab deruxtecan in patients with metastatic breast cancer.

Arnab Basu, MD, MPH, FACP, discusses his research on high sensitivity circulating tumor DNA assays in genitourinary malignancies.

Missak Haigentz, MD, discussed the implications and next steps of the ADRIATIC study in patients with limited-stage small cell lung cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib for the treatment of patients with unresectable stage III non–small cell lung cancer with EGFR mutations.

Geoffrey D. Young, MD, PhD, FACS, discussed the many advances in thyroid cancer management and treatment, highlighting what a community oncologist should be aware of.

Prithviraj Bose, MD, provides an overview of the different JAK inhibitors currently available for patients with myeloproliferative neoplasms.

Sun Gwe Ahn, MD, discusses an exploratory analysis of the HERA trial at the 2024 ESMO Congress.

Anil Parwani, MD, PhD, discusses the challenges and opportunities he has encountered in either implementing or utilizing artificial intelligence technology in the clinical setting.

Hamlet Gasoyan, MD, discusses what to know from a study that found there to be disparities in time to treatment with oral antimyeloma medications when used in patients with newly diagnosed multiple myeloma.

Jacob E. Berchuck, MD, discusses research behind using a blood-based liquid biopsy over traditional PSMA PET scans presented at the 2024 ESMO Congress.

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs among these patients.

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute lymphoblastic leukemia treatment.

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed the evolving role of transplant in myelodysplastic syndromes.

Francis P. Worden, MD, discusses a real-world study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer.

Alessandra Ferrajoli, MD, discusses the comorbidities that can impact the management of patients with chronic lymphocytic leukemia and some of the available treatment options in this space.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.

Stephen M. Ansell, MD, PhD, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology Annual Meeting in the advanced stage Hodgkin lymphoma space.

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.

Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced melanoma.

Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.

Kenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.